Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Appointed director

Myovant Sciences Ltd. (MYOV) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/20/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/10/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 100% stake in Myovant Sciences Ltd.
03/10/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/10/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/10/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
03/10/2023 8-K Appointed a new director
Docs: "BERMUDA THE COMPANIES ACT 1981 MEMORANDUM OF ASSOCIATION OF COMPANY LIMITED BY SHARES",
"AMENDED AND RESTATED BYE-LAWS OF Myovant Sciences Ltd. Bermuda Office Canon’s Court 22 Victoria Street Hamilton HM 12 Bermuda CONTENTS Bye-Law Page Interpretation 1 General Meetings 3 Notice of General Meetings 3 Proceedings at General Meetings 4 Voting 5 Proxies and Corporate Representatives 6 Written Resolutions of the Sole Member 8 Appointment and Removal of Directors 8 Register of Directors and Officers 9 Resignation and Disqualification of Directors 9 Alternate Directors 9 Directors’ Fees and Expenses 10 Directors’ Interests 10 Role and Powers of the Board 11 Proceedings of the Board 12 Officers 14 Secretary and Resident Representative 14 Issue of Shares 14 Purchase of Shares 15 Variation of Share Rights 15 Share Certificates 15 Non-Recognition of Trusts 16 Lien 16 Calls on Shares 17 ...",
"NEW YORK and BASEL, Switzerland, March 10, 2023"
03/06/2023 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 51.5% stake in Myovant Sciences Ltd.
03/01/2023 8-K Quarterly results
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/26/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/26/2023 8-K Quarterly results
Docs: "Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022"
01/23/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
01/23/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
01/06/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
01/06/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
12/08/2022 SC 13E3 Form SC 13E3 - Going private transaction by certain issuers:
12/08/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
10/26/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/26/2022 8-K Quarterly results
10/24/2022 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 51.7% stake in Myovant Sciences Ltd.
10/24/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy